Home LiteratureArticle Details
PMID: 10469169 Published · ppublish English Journal Article Review

New strategies in anti-vascular cancer therapy.

European journal of clinical investigation ·Vol. 29 ·No. 9 ·1999-09-00 ·Pages 802-9

Bloemendal HJ, Logtenberg T, Voest EE

Abstract

Angiogenesis is a critical step in the progression of tumours from dormancy to a clinical relevant cancer. Inhibition of this process is one of the most promising new anti-cancer strategies. To develop new drugs that interfere with the cascade of events required for the formation of new blood vessels, insight into this process is essential. Here, we discuss the molecular basis of angiogenesis and the concepts of vascular targeting. Furthermore new strategies will be discussed to discover surface markers on endothelial cells that confer sufficient specificity for targeted intervention in the tumour vasculature.

MeSH Terms
Antigens, Neoplasm Antineoplastic Agents/therapeutic use Biomarkers, Tumor Drug Design Endothelium, Vascular/drug effects Microcirculation/drug effects Neoplasms/blood supply,drug therapy Neovascularization, Pathologic/drug therapy Neovascularization, Physiologic/drug effects Peptide Library
Chemicals
Antigens, Neoplasm Antineoplastic Agents Biomarkers, Tumor Peptide Library
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Bloemendal H J
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
Logtenberg T
Voest E E
Article Info
Journal
European journal of clinical investigation
Abbr.
Eur J Clin Invest
ISSN
0014-2972
Published
1999-09-00
Pages
802-9
Language
English
Region
England
NLM ID
0245331
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com